Search clinical trials for: 3BNC117 10-1074

Total 3466 results

International AIDS Vaccine Initiative
Brigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller University

Active, not recruiting

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

HIV-1-infection

United States, Uganda, Kenya, Rwanda, South Africa
Advancing Clinical Therapeutics Globally for HIV...
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa (ACACIA)

HIV-1-infection
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Pausing Antiretroviral Treatment Under Structured Evaluation (PAUSE)

HIV-1-infection

Malawi, South Africa, Botswana
National Institute of Allergy and Infectious Diseases...
Rockefeller University

Withdrawn

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals

HIV

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

HIV-1

United States
Rockefeller University

Completed

3BNC117 and 10-1074 in HIV Uninfected Adults

Human Immunodeficiency Virus

United States
Imperial College London
Bill and Melinda Gates Foundation; University of Oxford; Rockefeller University

Recruiting

A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs). (RIO)

HIV/AIDS and Infections

Denmark, United Kingdom
University of Aarhus
Odense University Hospital; Oslo University Hospital; Rigshospitalet, Denmark; Hvidovre... and other collaborators

Completed

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV (TITAN)

HIV-1-infection

Norway, Denmark, United States, Australia
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection

HIV-1 Infection

United States
Rockefeller University

Completed

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

Human Immunodeficiency Virus

United States
National Institute of Allergy and Infectious Diseases...
Gilead Sciences; University of Oxford

Recruiting

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

HIV-1-infection

United States, Brazil
Rockefeller University
Brigham and Women's Hospital; Weill Medical College of Cornell University; University...

Completed

A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117

Healthy | HIV

United States, Germany
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Completed

3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals

Human Immunodeficiency Virus

United States
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Rockefeller University
University of Cologne

Completed

A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074

Healthy | HIV

Germany, United States
ANRS, Emerging Infectious Diseases
Institut Pasteur; Rockefeller University

Recruiting

Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control (RHIVIERA-02)

HIV/AIDS and Infections

France
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaborators

Completed

3BNC117 and 10-1074 in ART-treated Individuals

Human Immunodeficiency Virus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dual bNAb Treatment in Children

HIV Infection

Botswana
Rockefeller University
University Hospital of Cologne

Completed

3BNC117 and 10-1074 in HIV-infected Individuals

Human Immunodeficiency Virus (HIV)

United States, Germany
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Recruiting

3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

Human Immunodeficiency Virus

United States
National Institute of Allergy and Infectious Diseases...
ImmunityBio, Inc.; Rockefeller University

Recruiting

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants

HIV Infections

United States
University of Lausanne Hospitals

Completed

123I Radiolabeled 3BNC117

Human Immunodeficiency Virus

Switzerland
Rockefeller University

Completed

3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption

HIV-1 Infection

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions

HIV

United States
Frontier Biotechnologies Inc.

Unknown

Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

HIV/AIDS

United States
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers (NRX-1074)

Major Depressive Disorder

United States
Luis Montaner
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Unknown

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2) (BEAT-2)

HIV/AIDS | HIV | HIV-1 Infection

United States
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaborators

Completed

A Study of the Safety and Antiretroviral Activity of 3BNC117

HIV-1 Infection

United States
Rockefeller University

Completed

3BNC117-LS First-in-Human Phase 1 Study

Human Immunodeficiency Virus

United States
Frontier Biotechnologies Inc.

Unknown

Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

HIV/AIDS

China
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Curacle Co., Ltd.
KCRN Research, LLC

Completed

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

Diabetic Macular Edema

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Psoriasis

China
Hansoh BioMedical R&D Company

Recruiting

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Psoriasis

China
Frontier Biotechnologies Inc.

Recruiting

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL)

HIV-1-infection

United States
KBP Biosciences
Covance

Completed

Mass Balance Study of KBP-5074 in Healthy Male Subjects

Healthy

United States
KBP Biosciences

Completed

Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074

Healthy
Avidity Biosciences, Inc.

Enrolling by invitation

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping (EXPLORE44OLE)

Duchenne Muscular Dystrophy | DMD | Exon 44 | Duchenne

United States
Synvista Therapeutics, Inc

Completed

Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

Coronary Artery Disease | Diabetes

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Healthy

Netherlands
Bayside Health
Monash University; Austin Health; Rockefeller University; The Peter Doherty Institute... and other collaborators

Completed

Imaging the HIV Reservoir

HIV

Australia
KBP Biosciences
Covance

Completed

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

Healthy | Moderate Hepatic Impairment

United States
KBP Biosciences
Worldwide Clinical Trials

Completed

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease (BLOCKCKD)

Hypertension | Chronic Kidney Diseases

United States
NorthSea Therapeutics B.V.

Completed

A Phase 1, First Time in Humans Study of NST-1024

Hypertriglyceridemia

United Kingdom
Elixiron Immunotherapeutics Inc.
Parexel

Completed

A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers

Healthy Volunteers

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Moderate Hepatic Impairment | Normal Hepatic Function

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

Healthy | Renal Impairment

United States
Invicro

Completed

Assessment of [18F]MNI-1054 as a Marker for LSD1

Healthy Volunteers (HV)

United States

Search clinical trials for: 3BNC117 10-1074

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations